Dss Inc Stock Price, News & Analysis

Sentinel Brokers Company, a subsidiary of DSS (NYSE American: DSS), has received FINRA approval to act as an underwriter and selling group member for corporate securities offerings. This regulatory milestone enables Sentinel to participate in IPOs, follow-on offerings, and various corporate financing transactions.

Founded in 1996, Sentinel has established itself in institutional fixed income trading and expanded to equity market-making in 2021. The new FINRA approval allows the company to provide a comprehensive suite of services across multiple asset classes, enhancing its position in capital markets and ability to support corporate issuers and institutional clients throughout the capital formation process.

DSS (NYSE American: DSS) has announced the sale of its Celios® air purification technology to Impact BioMedical (NYSE American: IBO) in an all-equity transaction valued at $1.15 million. The strategic divestiture is part of DSS's portfolio optimization strategy to focus on core growth areas.

Celios® features a patented three-stage filtration system capable of removing ultrafine particles as small as 10 nanometers, enhancing indoor air quality and reducing airborne health risks. According to CEO Jason Grady, this transaction allows DSS to streamline its holdings and concentrate on business segments with stronger long-term synergies.

DSS, Inc. (NYSE American: DSS) announced significant operational improvements in their Q3 2024 financial performance. The company reported an 8% decrease in operating loss for both the three and nine-month periods ended September 30, 2024, compared to 2023. The net loss declined by 52% ($17.3 million) year-over-year for the nine months and 15% ($1.0 million) for the three-month period.

Cash flow from operations improved by $11.8 million (56%), with net cash position strengthening from $6.9 million to $11.8 million. The company completed the spin-off of Impact BioMedical in September 2024. Under new Interim CEO Jason Grady, DSS plans to reduce costs by 15-20% in the upcoming fiscal year, focus on expanding Premier Packaging, and enhance R&D initiatives in biomedical technologies and sustainable packaging.

DSS, Inc. (NYSE American: DSS) celebrates the successful IPO of Impact BioMedical Inc. (NYSE American: IBO), a company focused on healthcare and wellness solutions. The IPO was priced at $3.00 per share for 1,500,000 shares, with trading beginning on September 16, 2024 on the NYSE American Market. This milestone enhances shareholder value for DSS investors.

Key points:

• DSS distributed 4 shares of Impact BioMedical for every 1 DSS share held on July 10, 2023
• Underwriters received warrants to purchase up to 75,000 shares (or 86,250 if over-allotment is exercised)
• Warrants are exercisable at 125% of IPO price from 9 months after offering until the 3rd anniversary

Jason Grady, Interim CEO of DSS, expressed pride in Impact BioMedical's success and its alignment with DSS's commitment to shareholder returns.

AmericaFirst Funds, a subsidiary of DSS, Inc. (NYSE American: DSS), announced changes to its Board of Trustees. Three independent directors resigned on August 9, 2024, and three new directors were elected by shareholder proxy vote: Dr. Prabir Datta, Darryl Robinson, and Mark Gronet.

The new directors bring extensive experience in asset management, risk management, investment operations, and sales. Dr. Datta has a background in finance and operations, Robinson is a real estate industry veteran, and Gronet has expertise in institutional sales and human resources. These appointments aim to enhance the Trust's expertise and support its growth and success in the evolving investment landscape.

DSS, Inc. (NYSE American: DSS) has appointed Jason Grady as Interim CEO, effective August 23, 2024. Grady, previously COO, succeeds Frank D. Heuszel, who is transitioning to a leadership role at Impact Biomedical, a former DSS subsidiary. With over 25 years of executive experience, Grady has held key positions within DSS, including CEO of DSS Biohealth Holdings and President of Premier Packaging

Grady aims to lead DSS into its next growth phase, focusing on operational efficiency, revenue generation, and reducing cash burn. He acknowledges past challenges and is committed to enhancing shareholder value. This leadership change marks a pivotal moment for DSS as it navigates the evolving business landscape and strives to turn challenges into opportunities.